Merck logo

Merck

Merck & Co., Inc. is known as MSD outside the United States and Canada.

Its businesses span Pharmaceuticals, Vaccines and Animal Health.

ShareLink copied

The record

Stock
NYSE: MRK
14 Nov 2026.
Market capitalisation
About $364.3 billion
Market data. 13 Nov 2026.
Employees
Approximately 75,000
31 Dec 2025.
2025 revenue
$65.0 billion
Year ended 31 Dec 2025.
2025 R&D expenses
$15.8 billion
Year ended 31 Dec 2025.
Headquarters
Rahway, New Jersey
14 Nov 2026.

What they do

Merck & Co. is an American multinational pharmaceutical company based in Rahway, New Jersey. Outside the United States and Canada it operates as Merck Sharp & Dohme, or MSD. It develops and sells prescription medicines and vaccines, including a large oncology franchise built around Keytruda, as well as vaccines and animal health products.

Leadership & historical founders

Leadership as of 14 Nov 2026.

Merck & Co. is separate from Germany's Merck KGaA, whose history traces to 1668.

History and progression

How Merck got here, step by step.

  1. 1891

    Founded in New York

    Established on 1 January 1891 by George Merck, then 23, to distribute fine chemicals.

  2. 1933

    First research laboratory

    Opened its first research laboratory, in Rahway, New Jersey.

  3. 1953

    Merger with Sharp & Dohme

    Combined with Sharp & Dohme, creating Merck Sharp & Dohme (MSD).

  4. 1963

    First measles vaccine

    Launched the first measles vaccine, developed under Dr. Maurice Hilleman.

  5. 1987

    First statin and the Mectizan pledge

    Introduced the first commercial FDA-approved statin and committed to donate Mectizan "as much as needed for as long as needed" to help eliminate river blindness.

  6. 1996

    Record HIV approval

    Received FDA approval for an HIV medicine in a record 42 days, helping pave the way for combination therapy.

  7. 2006

    HPV vaccine and first DPP-4 inhibitor

    FDA approved its vaccine against cervical cancer caused by certain HPV types, and it launched the first DPP-4 inhibitor for type 2 diabetes.

  8. 2009

    Schering-Plough merger

    Completed its merger with Schering-Plough.

  9. 2014

    First anti-PD-1 therapy

    FDA approved the first anti-PD-1 therapy, Merck's immuno-oncology medicine.

  10. 2021

    Organon spinoff

    Completed the spinoff of Organon & Co. as an independent public company on 3 June 2021.

  11. 2024

    WINREVAIR approval

    FDA approved WINREVAIR (sotatercept-csrk) for adults with pulmonary arterial hypertension on 26 March 2024.

  12. 2025

    Verona Pharma acquisition

    Completed the acquisition of Verona Pharma for about $10 billion on 7 October 2025, adding OHTUVAYRE for COPD.

Clinical pipeline

Cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases and vaccines.

2025 Form 10-K.

Key products

KEYTRUDA and KEYTRUDA QLEX
Cancer immunotherapy
GARDASIL / GARDASIL 9
HPV vaccines
WINREVAIR
Pulmonary arterial hypertension
WELIREG
Belzutifan, oncology
ENFLONSIA
Clesrovimab, infant RSV prevention
OHTUVAYRE
Ensifentrine, COPD
CAPVAXIVE
Adult pneumococcal conjugate vaccine

Product snapshot, 29 Oct 2026.

Latest quarter

Q3 2026

  • Worldwide sales: $18.1 billion, up 5%.
  • KEYTRUDA and KEYTRUDA QLEX sales: $8.6 billion.
  • WINREVAIR sales: $694 million, up 93%.

Reported 29 Oct 2026.

Recent Merck releases

  1. 13 Nov 2026

    Positive EU CHMP opinion to expand ENFLONSIA to children up to 24 months at increased risk through their second RSV season
  2. 13 Nov 2026

    Positive EU CHMP opinion for WELIREG plus lenvatinib in advanced clear cell renal cell carcinoma after anti-PD-1/PD-L1 therapy
  3. 9 Nov 2026

    Positive Phase 2b efinopegdutide results in MASH with stage 2 to 3 fibrosis, presented at The Liver Meeting and published in The Lancet
  4. 3 Nov 2026

    ENHANCE-3 Phase 3 study begins, evaluating OHTUVAYRE for preventing COPD exacerbations
  5. 29 Oct 2026

    Third-quarter financial results and pipeline milestones

WINREVAIR: HYPERION and pulmonary arterial hypertension

Pneumococcal vaccines: VAX-31 and CAPVAXIVE

In our newsletter

The Variational AI collaboration briefing

The Merck and Moderna vaccine briefing

Related companies

Related funding

Your daily HealthTech Signal

No hype. Just signal.

Get the latest HealthTech news, understand why it matters, and see where the industry is headed.

5-minute read Delivered daily Unsubscribe anytime

Read by teams at companies like:

Mayo Clinic logoMayo ClinicCleveland Clinic logoCleveland ClinicJohns Hopkins logoJohns HopkinsKaiser Permanente logoKaiser PermanenteEpic logoEpicPhilips logoPhilipsMedtronic logoMedtronicGE HealthCare logoGE HealthCare

Is this your company? Get a Verified profile